N
Nuubo
Biotech & Life Sciences · Madrid, Spain · Founded 2005
Envisions wireless health and remote monitoring of physiological parameters as a simple, transparent and non-intrusive experience that should be available to anyone, anywhere MoreLess
Nuubo, a Spanish medical technology company established in 2005, specializes in wearable solutions for remote cardiac monitoring. The company was founded by Agustín Macià Barber and Luis Sanchez Morales, who now serve as CTO and CFO/COO respectively. The leadership team also includes CEO Juan Alcántara Morales, who brought over two decades of experience from the medical device sector when he joined in 2013. Nuubo operates from its Madrid headquarters, with research, development, and manufacturing facilities located in Valencia.
The company's core business involves designing, manufacturing, and selling a proprietary portfolio of wireless medical technologies aimed at prevention, diagnosis, and rehabilitation. Its primary clients are healthcare professionals and institutions, particularly in the fields of cardiology and stroke care. Nuubo has established a significant presence in Spain, with its technology used in 75% of stroke units and 60% of cardiology departments. The business model centers on selling its integrated monitoring system to these healthcare providers. The firm has successfully raised capital to fuel its growth, including a significant investment round in May 2024 to support expansion into the U.S. market.
Nuubo's flagship product is the Nuubo System, an ambulatory electrocardiogram (aECG) monitoring solution. This system comprises three main components: a wearable textile garment (Nuubo30) embedded with biomedical sensors, a wireless recording device (NuuboREC) that captures ECG data, and the Leonardo software for data analysis by clinicians. A key feature is its use of biomedical textiles with 3D-printed biosensors, which eliminates the need for adhesive electrodes and cables, enhancing patient comfort and compliance. This technology allows for continuous, non-invasive monitoring for up to 30 days, a significant increase compared to the 24-48 hour window of traditional Holter monitors, thereby increasing the diagnostic yield for conditions like atrial fibrillation. The system has received both CE mark and FDA 510(k) clearance.
Keywords: cardiac monitoring, wearable medical device, electrocardiogram, ECG, arrhythmia diagnosis, remote patient monitoring, medical textiles, biosensors, medtech, cardiovascular health, atrial fibrillation, stroke prevention, long-term ECG, Holter monitor alternative, wireless health, digital health, non-invasive monitoring, telehealth technology, medical device manufacturing, cardiac rehabilitation
Talent graph
Nuubo's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Nuubo has talent and traffic
team presence
Market sentiment
What the market is saying about Nuubo
An AI-synthesized read of the highest-engagement posts about Nuubo on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nuubo on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.





